J.E. LaDow et al. / European Journal of Medicinal Chemistry 46 (2011) 4219e4226
4225
kill within 30 min, while MC14 (12) was unable to kill the pop-
ulation of cells at 72 h. The drastic difference in efficiency at killing
E. coli by the two monocations (11, 12) suggests that tail length is
critical for killing this Gram-negative organism, with the shorter
chain length more effective. Tail length of the monocations may not
be as important when killing Gram-positive bacteria since the
difference was minimal.
48, and 72 h, one-hundred microliter aliquots were plated on TSA
plates, and the plates were incubated overnight at 37 ꢃC. Data
reported are times when no colonies were observed growing on
plates after overnight incubation. Additionally, 100
ml of cells
treated with compounds for 72 h were placed on slides, Gram-
stained, and visualized microscopically to determine if intact cells
were still present after treatment.
5. Conclusions
Acknowledgements
Our results indicate a moderate set of structure-activity relation-
ships for this synthesized series of bicephalic amphiphiles, specifi-
cally favoring the 3,5- and 2,4-substitution series, as well as extended
chain length for speed in bacterial killing assays. Only biscationic
amphiphiles maintained good activity versus the Gram-negative
bacteria tested. Armed with this knowledge, we aim to extend our
investigations into optimized and novel architectures in this series.
Longer chain derivatives of the 3,5-substitution pattern are high
priorities for future investigations, as well as compounds with alter-
nate head group structures. Finally, we aim to broaden our under-
standing of the interdependence of activity against specific bacteria,
thus a larger battery of test organisms will also be investigated.
This work was primarily supported by a Multi-Investigator
Cottrell College Science Award from the Research Corporation for
Science Advancement (to KLC, KPCM, and KS; MICCSA 10709).
Additional support came from the American Chemical Society
Petroleum Research Fund (to KLC; 43543-GB4), Research Corpora-
tion (to KLC, CC5948), the US Department of Defense ASSURE
program (to KLC; DMR-0851367), and the National Science Foun-
dation e REU program (CHE-0754521).
Appendix. Supplementary material
Supplementary data associated with this article can be found, in
include synthetic details, MOL files and InChIKeys of the most
important compounds described in this article.
6. Experimental section
6.1. Bacterial strains and culture conditions
References
Bacterial strains S. aureus subsp. aureus ATCCÒ 29213Ô, E. fae-
calis ATCCÒ 29212Ô, E. coli ATCCÒ 25922Ô, and P. aeruginosa strain
Boston 41501 ATCCÒ 27853Ô were obtained from the American
type Culture Collection (ATCC, Manassas, VA, USA). S. aureus and
E. faecalis are Gram-positive pathogens, P. aeruginosa is a Gram-
negative pathogen, and E. coli is a non-pathogenic Gram-negative
organism. All strains are reference strains for the Clinical and
Laboratory Standards Institute (CLSI) for antimicrobial suscepti-
bility testing of nonfastidious bacteria, and were grown in Mueller-
Hinton broth at 37 ꢃC as recommended [35].
[1] B.L. Johnston, E. Bryce, Hospital infection control strategies for vancomycin-
resistant Enterococcus, methicillin-resistant Staphylococcus aureus and Clos-
tridium difficile, CMAJ 180 (2009) 627e631.
[2] P. Gilbert, L.E. Moore, Cationic antiseptics: diversity of action under a common
epithet, J. Appl. Microbiol. 99 (2005) 703e715.
[3] G.W. Kaatz, S.M. Seo, C.A. Ruble, Efflux-mediated fluoroquinolone resistance in
Staphylococcus aureus, Antimicrob. Agents Chemother. 37 (1993) 1086e1094.
[4] B.E. Murray, Problems and dilemmas of antimicrobial resistance, Pharmaco-
therapy 12 (1992).
[5] G. Taubes, The bacteria fight back, Science 321 (2008) 356e361.
[6] F. Fan, K. Yan, N.G. Wallis, S. Reed, T.D. Moore, S.F. Rittenhouse, W.E. DeWolf Jr.,
J. Huang, D. McDevitt, W.H. Miller, M.A. Seefeld, K.A. Newlander, D.R. Jakas,
M.S. Head, D.J. Payne, Defining and combating the mechanisms of triclosan
resistance in clinical isolates of Staphylococcus aureus, Antimicrob. Agents
Chemother. 46 (2002) 3343e3347.
6.2. Broth microdilution MIC and MBC determination
[7] P. Gjermo, Chlorhexidine and related compounds, J. Dent. Res. 68 (1989)
1602e1608.
[8] H.A. Lilly, E.J. Lowbury, Disinfection of the skin: an assessment of some new
preparations, Br. Med. J. 3 (1971) 674e676.
[9] J. Haldar, P. Kondaiah, S. Bhattacharya, Synthesis and antibacterial properties
of novel hydrolyzable cationic amphiphiles. Incorporation of multiple head
groups leads to impressive antibacterial activity, J. Med. Chem. 48 (2005)
3823e3831.
[10] J. Pernak, M. Branicka, The properties of 1-alkoxymethyl-3-hydroxypyridinium
and 1-alkoxymethyl-3-dimethylaminopyridinium chlorides, J. Surfactants
Detergents 6 (2003) 119e123.
[11] G. Viscardi, P. Quagliotto, C. Barolo, P. Savarino, E. Barni, E. Fisicaro, Synthesis
and surface and antimicrobial properties of novel cationic surfactants, J. Org.
Chem. 65 (2000) 8197e8203.
[12] S. Bera, G.G. Zhanel, F. Schweizer, Evaluation of amphiphilic aminoglycoside-
peptide triazole conjugates as antibacterial agents, Bioorg. Med. Chem. Lett.
20 (2010) 3031e3035.
[13] P. Madaan, V.K. Tyagi, Synthesis and characterization of the antimicrobial 4-
amino-decylpyridinium bromide cationic surfactant, Surf. Rev. Lett. 15
(2008) 531e536.
[14] S. Roy, P.K. Das, Antibacterial hydrogels of amino acid-based cationic
amphiphiles, Biotechnol. Bioeng. 100 (2008) 756e764.
[15] R.N. Mitra, A. Shome, P. Paul, P.K. Das, Antimicrobial activity, biocompatibility
and hydrogelation ability of dipeptide-based amphiphiles, Org. Biomol. Chem.
7 (2009) 94e102.
[16] S. Debnath, A. Shome, D. Das, P.K. Das, Hydrogelation through self-assembly of
fmoc-peptide functionalized cationic amphiphiles: potent antibacterial agent,
J. Phys. Chem. B. 114 (2010) 4407e4415.
[17] S.N. Jampala, M. Sarmadi, E.B. Somers, A.C.L. Wong, F.S. Denes, Plasma-
enhanced synthesis of bactericidal quaternary ammonium thin layers on
stainless steel and cellulose surfaces, Langmuir 24 (2008) 8583e8591.
[18] Z. Tong, F. Widmer, T.C. Sorrell, Z. Guse, K.A. Jolliffe, C. Halliday, C.L. Ok,
F. Kong, L.C. Wright, S.C.A. Chen, In vitro activities of miltefosine and two
The broth microdilution for determining the MIC and MBC of
antimicrobial compounds was performed as previously described
[35]. Briefly, all compounds were serially diluted and 100 ml of each
dilution was added to microtiter plate wells in triplicate. Overnight
cultures of bacterial cells were diluted to a final inoculum of
approximately 5 ꢀ 106 cfu/mL, and 100
ml of this suspension was
added to all wells yielded 5 ꢀ 105 cfu/well. Cell concentrations and
viability were verified by serial dilution and plating for each
experiment. Microtiter plates were incubated at 37 ꢃC for 72 h. The
MIC was determined as the lowest concentration of compound to
completely inhibit growth as detected by the unaided eye. From
each set of triplicate wells, 100 ml was then plated on trypticase soy
agar (TSA) and incubated for 24 h and examined to determine the
MBC values for each compound. The MBC was determined as the
lowest concentration of compound at which there were no colonies
growing on the plate. MIC and MBC experiments were performed
a minimum of 3 times for each organism.
6.3. Bacterial killing assays
To determine the relative temporal effectiveness of the
synthesized amphiphiles, overnight cultures were diluted in broth
to a concentration of 2.5 ꢀ 106 cfu/ml. Compounds were added to
the cultures to a final concentration of 100 mM, and tubes were
incubated at room temperature. At 15, 30, 60, 90, 120, 180 min, 24,